Evidence based review of medicines for sexual dysfunction in females: a report commissioned by the New Zealand Accident Compensation Corporation (ACC)

Stewart C
Record ID 32004000808
English
Authors' objectives:

ACC is occasionally called on to fund treatment for female claimants with sexual dysfunction caused by damage due to accident or injury. However, there appears to be little evidence on the usefulness of such products for women generally. The objective of the report is to identify what evidence (if any) there is to support the use of sexual dysfunction medicines in women experiencing sexual dysfunction due to accident or injury. The products investigated (source: May 2003 New Ethicals Catalogue) are: - Cialis (tadalafil) tablets - Levitra (vardenafil hydrocholoride trihydrate) tablets - Uprima SL (apomorphine) tablets, sublingual - Viagra (sildenafil) tablets.

Authors' recommendations: Only a small number of good quality studies evaluating the efficacy and safety of female sexual dysfunction medicines were found. From the studies that are available, there is limited or no evidence that the listed medicines (sildenafil, tadalafil, vardenafil, apomorphine SL) or any other pharmacological treatments are effective and safe treatments for female sexual dysfunction. Indeed, approval is no longer being sought for sildenafil as a treatment for female sexual dysfunction. There is currently no substantive evidence available in terms of clinically significant outcomes for any of the proposed pharmacological treatments for women with sexual dysfunction caused by damage due to accident or injury.
Authors' methods: Systematic review
Details
Project Status: Completed
Year Published: 2004
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: New Zealand
MeSH Terms
  • Accidents
  • Female
  • Sexual Dysfunction, Physiological
  • Wounds and Injuries
Contact
Organisation Name: New Zealand Health Technology Assessment
Contact Address: Department of Public Health and General Practice, Christchurch School of Medicine and Health Sciences, University of Otago, P.O. Box 4345, Christchurch, New Zealand. Tel: +64 3 364 1145; Fax: +64 3 364 1152;
Contact Name: nzhta@chmeds.ac.nz
Contact Email: nzhta@chmeds.ac.nz
Copyright: New Zealand Health Technology Assessment (NZHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.